Imiquimod 5% cream in the treatment of Bowen’s disease and invasive squamous cell carcinoma - 09/08/11
, Tamara Micantonio, MD a, Maria Concetta Fargnoli, MD a, Gian Piero Lozzi, MD a, Sergio Chimenti, MD b
Reprint requests: Ketty Peris, MD, Department of Dermatology, University of L’Aquila, Via Vetoio–Coppito 2, 67100 L’Aquila, Italy.L’Aquila and Rome, Italy
Abstract |
Background |
Imiquimod has been successfully used for treatment of various epithelial cutaneous neoplasms.
Objective |
Our aim was to evaluate the efficacy and tolerability of imiquimod 5% cream for treatment of Bowen’s disease and invasive squamous cell carcinoma (SCC) in patients who were unsuitable candidates for surgery.
Method |
Five Bowen’s disease lesions and 7 invasive SCC lesions on 10 patients were treated with imiquimod once daily 5 times a week for a maximum of 16 weeks.
Results |
After 8 to 12 weeks of treatment, 4 of 5 Bowen’s disease lesions (80%) and 5 of 7 invasive SCCs (71.4%) showed complete clinicopathologic regression. The remaining 3 lesions showed partial regression after 16 weeks of treatment. No recurrence has been detected after a follow-up period of 24 to 38 months (mean, 31 months).
Limitations |
The study is an open-label clinical trial on a small number of selected patients, with lack of excision with serial step sections.
Conclusion |
Topical application of imiquimod 5% cream might represent an alternative topical treatment to surgery in selected cases of Bowen’s disease and invasive SCC.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None identified. |
Vol 55 - N° 2
P. 324-327 - août 2006 Retour au numéro
Article précédent
- Preferred methods of excess hair removal in pediatric patients with lung transplantation
- Emily J. Fisher, David R. Berk, Riley E. Greene, Pegi Shaner, Stuart C. Sweet, Susan Bayliss Mallory
- Cutaneous complications of intravesical treatments for bladder cancer: Granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy
- Faraz Kureshi, Amer N. Kalaaji, Larry Halvorson, Mark R. Pittelkow, Mark D.P. Davis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?